Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-ca...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/9/4/166 |
id |
doaj-083b2390ca2c43aa95061a6a383f9d8d |
---|---|
record_format |
Article |
spelling |
doaj-083b2390ca2c43aa95061a6a383f9d8d2020-11-25T01:33:52ZengMDPI AGDiagnostics2075-44182019-10-019416610.3390/diagnostics9040166diagnostics9040166Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic SignatureHideki Furuya0Ian Pagano1Keanu Chee2Takashi Kobayashi3Regan S. Wong4Riko Lee5Charles J. Rosser6Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACancer Prevention in the Pacific Program University of Hawaii Cancer Center, Honolulu, HI 96813, USATranslational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USADepartment of Urology, Kyoto University, Kyoto 606-8507, JapanDivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USATranslational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USADivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USAThe ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.https://www.mdpi.com/2075-4418/9/4/166biomarkersbladder cancermultiplexproteinurine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hideki Furuya Ian Pagano Keanu Chee Takashi Kobayashi Regan S. Wong Riko Lee Charles J. Rosser |
spellingShingle |
Hideki Furuya Ian Pagano Keanu Chee Takashi Kobayashi Regan S. Wong Riko Lee Charles J. Rosser Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature Diagnostics biomarkers bladder cancer multiplex protein urine |
author_facet |
Hideki Furuya Ian Pagano Keanu Chee Takashi Kobayashi Regan S. Wong Riko Lee Charles J. Rosser |
author_sort |
Hideki Furuya |
title |
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_short |
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_full |
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_fullStr |
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_full_unstemmed |
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_sort |
comparison of commercial elisa kits, a prototype multiplex electrochemoluminescent assay, and a multiplex bead-based immunoassay for detecting a urine-based bladder-cancer-associated diagnostic signature |
publisher |
MDPI AG |
series |
Diagnostics |
issn |
2075-4418 |
publishDate |
2019-10-01 |
description |
The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens. |
topic |
biomarkers bladder cancer multiplex protein urine |
url |
https://www.mdpi.com/2075-4418/9/4/166 |
work_keys_str_mv |
AT hidekifuruya comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT ianpagano comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT keanuchee comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT takashikobayashi comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT reganswong comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT rikolee comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT charlesjrosser comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature |
_version_ |
1725075298623422464 |